Beta-catenin

From Wikipedia, the free encyclopedia

CTNNB1

Available structures
Ortholog search: PDBe RCSB
PDB
[show]List of PDB id codes
Identifiers
CTNNB1, CTNNB, MRD19, armadillo, catenin beta
Aliases
1
External OMIM: 116806 MGI: 88276 HomoloGene: 1434
IDs GeneCards: CTNNB1
[show]Gene ontology
RNA expression pattern

More reference expression data

Orthologs
Species Human Mouse
Entrez 1499 12387
Ensembl ENSG00000168036 ENSMUSG00000006932
UniProt P35222 Q02248
RefSeq NM_001098209 NM_001165902
(mRNA) NM_001098210 NM_007614
 NM_001904
NM_001330729
NP_001091679
RefSeq NP_001091680 NP_001159374
(protein) NP_001317658 NP_031640
NP_001895
Location Chr 3: 41.19 – 41.26
Chr 9: 120.93 – 120.96 Mb
(UCSC) Mb
PubMed [1] [2]
search
Wikidata
View/Edit Human View/Edit Mouse

Catenin beta-1, also known as β-catenin, is a protein that in humans is encoded by the
CTNNB1 gene.

β-catenin is a dual function protein, involved in regulation and coordination of cell–cell

adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1
gene.[3][4] In Drosophila, the homologous protein is called armadillo. β-catenin is a subunit of
the cadherin protein complex and acts as an intracellular signal transducer in the Wnt
signaling pathway.[5][6][7] It is a member of the catenin protein family and homologous to γ-
catenin, also known as plakoglobin. Beta-catenin is widely expressed in many tissues. In
cardiac muscle, beta-catenin localizes to adherens junctions in intercalated disc structures,
which are critical for electrical and mechanical coupling between adjacent cardiomyocytes.

Mutations and overexpression of β-catenin are associated with many cancers, including
hepatocellular carcinoma, colorectal carcinoma, lung cancer, malignant breast tumors,
ovarian and endometrial cancer.[8] Alterations in the localization and expression levels of
beta-catenin have been associated with various forms of heart disease, including dilated
cardiomyopathy. β-catenin is regulated and destroyed by the beta-catenin destruction
complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the
tumour-suppressing APC gene. Therefore, genetic mutation of the APC gene is also strongly
linked to cancers, and in particular colorectal cancer resulting from familial adenomatous
polyposis (FAP).

Contents
 1 Discovery
 2 Structure
o 2.1 Protein structure
o 2.2 Partners binding to the armadillo domain
 3 Function
o 3.1 Regulation of degradation through phosphorylation
o 3.2 The beta-catenin destruction complex
o 3.3 Wnt signaling and the regulation of destruction
o 3.4 Role in cell-cell adhesion
o 3.5 Roles in development
 3.5.1 Early embryonic patterning
  3.5.2 Asymmetric cell division
 3.5.3 Stem cell renewal
 3.5.4 Epithelial-to-mesenchymal transition
o 3.6 Involvement in cardiac physiology
 4 Clinical significance
o 4.1 Role in depression
o 4.2 Role in cardiac disease
o 4.3 Involvement in cancer
o 4.4 As a therapeutic target
o 4.5 Role in fetal alcohol syndrome
 5 Interactions
 6 See also
 7 References
 8 Further reading
 9 External links

Discovery
Beta-catenin was initially discovered in the early 1990s as a component of a mammalian cell
adhesion complex: a protein responsible for cytoplasmatic anchoring of cadherins.[9] But very
soon, it was realized that the Drosophila protein armadillo – implicated in mediating the
morphogenic effects of Wingless/Wnt – is homologous to the mammalian β-catenin, not just
in structure but also in function.[10] Thus beta-catenin became one of the very first examples
of moonlighting: a protein performing more than one radically different cellular function.

Structure
Protein structure

The core of beta-catenin consists of several very characteristic repeats, each approximately
40 amino acids long. Termed armadillo repeats, all these elements fold together into a single,
rigid protein domain with an elongated shape – called armadillo (ARM) domain. An average
armadillo repeat is composed of three alpha helixes. The first repeat of β-catenin (near the N-
terminus) is slightly different from the others – as it has an elongated helix with a kink,
formed by the fusion of helices 1 and 2.[11] Due to the complex shape of individual repeats,
the whole ARM domain is not a straight rod: it possesses a slight curvature, so that an outer
(convex) and an inner (concave) surface is formed. This inner surface serves as a ligand-
binding site for the various interaction partners of the ARM domains.
The simplified structure of beta-catenin.

The segments N-terminal and far C-terminal to the ARM domain do not adopt any structure
in solution by themselves. Yet these intrinsically disordered regions play a crucial role in
beta-catenin function. The N-terminal disordered region contains a conserved short linear
motif responsible for binding of TrCP1 (also known as β-TrCP) E3 ubiquitin ligase – but
only when it is phosphorylated. Degradation of β-catenin is thus mediated by this N-terminal
segment. The C-terminal region, on the other hand, is a strong transactivator when recruited
onto DNA. This segment is not fully disordered: part of the C-terminal extension forms a
stable helix that packs against the ARM domain, but may also engage separate binding
partners.[12] This small structural element (HelixC) caps the C-terminal end of the ARM
domain, shielding its hydrophobic residues. HelixC is not necessary for beta-catenin to
function in cell-cell adhesion. On the other hand, it is required for Wnt signaling: possibly to
recruit various coactivators. Yet its exact partners among the general transcription complexes
are still unknown. Notably, the C-terminal segment of β-catenin can mimic the effects of the
entire Wnt pathway if artificially fused to the DNA binding domain of LEF1 transcription
factor.[13]

Plakoglobin (also called gamma-catenin) has a strikingly similar architecture to that of beta-
catenin. Not only their ARM domains resemble each other in both architecture and ligand
binding capacity, but the N-terminal β-TrCP-binding motif is also conserved in plakoglobin,
implying common ancestry and shared regulation with β-catenin.[14] However, plakoglobin is
a very weak transactivator when bound to DNA – this is probably caused by the divergence
of their C-terminal sequences (plakoglobin appears to lack the transactivator motifs, and thus
inhibits the Wnt pathway target genes instead of activating them).[15]

Partners binding to the armadillo domain

Partners competing for the main binding site on the ARM domain of beta-catenin. The
auxiliary binding site is not shown.

As sketched above, the ARM domain of beta-catenin acts as a platform to which specific
linear motifs may bind. Located in structurally diverse partners, the β-catenin binding motifs
are typically disordered on their own, and typically adopt a rigid structure upon ARM domain
engagement – as seen for short linear motifs. However, β-catenin interacting motifs also have
a number of peculiar characteristics. First, they might reach or even surpass the length of 30
amino acids in length, and contact the ARM domain on an excessively large surface area.
Another unusual feature of these motifs is their frequently high degree of phosphorylation.
Such Ser/Thr phosphorylation events greatly enhance the binding of many β-catenin
associating motifs to the ARM domain.[16]

The structure of beta-catenin in complex with the catenin binding domain of the
transcriptional transactivation partner TCF provided the initial structural roadmap of how
many binding partners of beta-catenin may form interactions.[17] This structure demonstrated
how the otherwise disordered N-terminus of TCF adapted what appeared to be a rigid
conformation, with the binding motif spanning many beta-catenin repeats. Relatively strong
charged interaction "hot spots" were defined (predicted, and later verified, to be conserved for
the beta-catenin/E-cadherin interaction), as well as hydrophobic regions deemed important in
the overall mode of binding and as potential therapeutic small molecule inhibitor targets
against certain cancer forms. Furthermore, following studies demonstrated another peculiar
characteristic, plasticity in the binding of the TCF N-terminus to beta-catenin.[18][19]

Similarly, we find the familiar E-cadherin, whose cytoplasmatic tail contacts the ARM
domain in the same canonical fashion.[20] The scaffold protein axin (two closely related
paralogs, axin 1 and axin 2) contains a similar interaction motif on its long, disordered middle
segment.[21] Although one molecule of axin only contains a single β-catenin recruitment
motif, its partner the Adenomatous Polyposis Coli (APC) protein contains 11 such motifs in
tandem arrangement per protomer, thus capable to interact with several β-catenin molecules
at once.[22] Since the surface of the ARM domain can typically accommodate only one
peptide motif at any given time, all these proteins compete for the same cellular pool of β-
catenin molecules. This competition is the key to understand how the Wnt signaling pathway
works.

However, this "main" binding site on the ARM domain β-catenin is by no means the only
one. The first helices of the ARM domain form an additional, special protein-protein
interaction pocket: This can accommodate a helix-forming linear motif found in the
coactivator BCL9 (or the closely related BCL9L) – an important protein involved in Wnt
signaling.[23] Although the precise details are much less clear, it appears that the same site is
used by alpha-catenin when beta-catenin is localized to the adherens junctions.[24] Because
this pocket is distinct from the ARM domain's "main" binding site, there is no competition
between alpha-catenin and E-cadherin or between TCF1 and BCL9, respectively.[25] On the
other hand, BCL9 and BCL9L must compete with α-catenin to access β-catenin molecules.[26]

Function
Regulation of degradation through phosphorylation

The cellular level of beta-catenin is mostly controlled by its ubiquitination and proteosomal
degradation. The E3 ubiquitin ligase TrCP1 (also known as β-TrCP) can recognize β-catenin
as its substrate through a short linear motif on the disordered N-terminus. However, this motif
(Asp-Ser-Gly-Ile-His-Ser) of β-catenin needs to be phosphorylated on the two serines in
order to be capable to bind β-TrCP. Phosphorylation of the motif is performed by Glycogen
Synthase Kinase 3 alpha and beta (GSK3α and GSK3β). GSK3s are constitutively active
enzymes implicated in several important regulatory processes. There is one requirement,
though: substrates of GSK3 need to be pre-phosphorylated four amino acids downstream (C-
terminally) of the actual target site. Thus it also requires a "priming kinase" for its activities.
In the case of beta-catenin, the most important priming kinase is Casein Kinase I (CKI). Once
a serin-threonine rich substrate has been "primed", GSK3 can "walk" across it from C-
terminal to N-terminal direction, phosphorylating every 4th serine or threonine residues in a
row. This process will result in dual phosphorylation of the aforementioned β-TrCP
recognition motif as well.

The beta-catenin destruction complex

For GSK3 to be a highly effective kinase on a substrate, pre-phosphorylation is not enough.

There is one additional requirement: Similar to the mitogen-activated protein kinases
(MAPKs), substrates need to associate with this enzyme through high-affinity docking motifs.
Beta-catenin contains no such motifs, but a special protein does: axin. What is more, its
GSK3 docking motif is directly adjacent to a β-catenin binding motif.[21] This way, axin acts
as a true scaffold protein, bringing an enzyme (GSK3) together with its substrate (β-catenin)
into close physical proximity.
Simplified structure of the beta-catenin destruction complex. Note the high proportion of
intrinsically disordered segments in the axin and APC proteins.

But even axin does not act alone. Through its N-terminal regulator of G-protein signaling
(RGS) domain, it recruits the adenomatous polyposis coli (APC) protein. APC is like a huge
"Christmas tree": with a multitude of β-catenin binding motifs (one APC molecule alone
possesses 11 such motifs [22]), it may collect as many β-catenin molecules as possible.[27] APC
can interact with multiple axin molecules at the same time as it has three SAMP motifs (Ser-
Ala-Met-Pro) to bind the RGS domains found in axin. In addition, axin also has the potential
to oligomerize through its C-terminal DIX domain. The result is a huge, multimeric protein
assembly dedicated to β-catenin phosphorylation. This complex is usually called the beta-
catenin destruction complex, although it is distinct from the proteosome machinery actually
responsible for β-catenin degradation.[28] It only marks β-catenin molecules for subsequent
destruction.

Wnt signaling and the regulation of destruction

In resting cells, axin molecules oligomerize with each other through their C-terminal DIX
domains, which have two binding interfaces. Thus they can build linear oligomers or even
polymers inside the cytoplasm of cells. DIX domains are unique: the only other protein
known to have a DIX domain is Dishevelled. (The single Dsh protein of Drosophila
corresponds to three paralogous genes, Dvl1, Dvl2 and Dvl3 in mammals.) Dsh associates
with the cytoplasmic regions of Frizzled receptors with its PDZ and DEP domains. When a
Wnt molecule binds to Frizzled, it induces a poorly known cascade of events, that result in
the exposure of dishevelled's DIX domain and the creation of a perfect binding site for axin.
Axin is then titrated away from its oligomeric assemblies – the β-catenin destruction complex
– by Dsh.[29] Once bound to the receptor complex, axin will be rendered incompetent for β-
catenin binding and GSK3 activity. Importantly, the cytoplasmic segments of the Frizzled-
associated LRP5 and LRP6 proteins contain GSK3 pseudo-substrate sequences (Pro-Pro-Pro-
Ser-Pro-x-Ser), appropriately "primed" (pre-phosphorylated) by CKI, as if it were a true
substrate of GSK3. These false target sites greatly inhibit GSK3 activity in a competitive
manner.[30] This way receptor-bound axin will abolish mediating the phosphorylation of β-
catenin. Since beta-catenin is no longer marked for destruction, but continues to be produced,
its concentration will increase. Once β-catenin levels rise high enough to saturate all binding
sites in the cytoplasm, it will also translocate into the nucleus. Upon engaging the
transcription factors LEF1, TCF1, TCF2 or TCF3, β-catenin forces them to disengage their
previous partners: Groucho proteins. Unlike Groucho, that recruit transcriptional repressors
(e.g. histone-lysine methyltransferases), beta-catenin will bind transcriptional activators,
switching on target genes.

Role in cell-cell adhesion

The moonlighting of beta-catenin.

Cell–cell adhesion complexes are essential for the formation of complex animal tissues. β-
catenin is part of a protein complex that form the so-called adherens junctions.[31] These cell-
cell adhesion complexes are necessary for the creation and maintenance of epithelial cell
layers and barriers. As a component of the complex, β-catenin can regulate cell growth and
adhesion between cells. It may also be responsible for transmitting the contact inhibition
signal that causes cells to stop dividing once the epithelial sheet is complete.[32] The E-
cadherin – β-catenin – α-catenin complex is weakly associated to actin filaments. Adherent
junctions thus form a dynamic, rather than a stable link to the actin cytoskeleton.[31]

The heart of the adherent junctions are the cadherin proteins. Cadherins form the cell-cell
junctional structures known as adherens junctions as well as the desmosomes. Cadherins are
capable of homophilic interactions through their extracellular cadherin repeat domains, in a
Ca2+-dependent manner: this can hold adjacent epithelial cells together. While in the
adherens junction, cadherins recruit β-catenin molecules onto their intracellular regions. β-
catenin, in turn, associates with another important protein, α-catenin that directly binds to the
actin filaments.[33] This is possible because α-catenin and cadherins bind at distinct sites to β-
catenin. The β-catenin – α-catenin complex can thus physically bridge cadherins with the
actin cytoskeleton.[34] Organization of the cadherin–catenin complex is additionally regulated
through phosphorylation and endocytosis of its components.

Roles in development

Beta-catenin has a central role in directing several developmental processes, as it can directly
bind transcription factors and be regulated by a diffusible extracellular substance: Wnt. It acts
upon early embryos to induce entire body regions, as well as individual cells in later stages of
development. It also regulates physiological regeneration processes.

Early embryonic patterning

Wnt signaling and beta-catenin dependent gene expression plays a critical role during the
formation of different body regions in the early embryo. Experimentally modified embryos
that do not express this protein will fail to develop mesoderm and initiate gastrulation.[35]
During the blastula and gastrula stages, Wnt as well as BMP and FGF pathways will induce
the antero-posterior axis formation, regulate the precise placement of the primitive streak
(gastrulation and mesoderm formation) as well as the process of neurulation (central nervous
system development).[36]

In Xenopus oocytes, β-catenin is initially equally localized to all regions of the egg, but it is
targeted for ubiquitination and degradation by the β-catenin destruction complex.
Fertilization of the egg causes a rotation of the outer cortical layers, moving clusters of the
Frizzled and Dsh proteins closer to the equatorial region. β-catenin will be enriched locally
under the influence of Wnt signaling pathway in the cells that inherit this portion of the
cytoplasm. It will eventually translocate to the nucleus to bind TCF3 in order to activate
several genes that induce dorsal cell characteristics.[37] This signaling results in a region of
cells known as the grey crescent, which is a classical organizer of embryonic development. If
this region is surgically removed from the embryo, gastrulation does not occur at all. β-
Catenin also plays a crucial role in the induction of the blastopore lip, which in turn initiates
gastrulation.[38] Inhibition of GSK-3 translation by injection of antisense mRNA may cause a
second blastopore and a superfluous body axis to form. A similar effect can result from the
overexpression of β-catenin.[39]

Asymmetric cell division

Beta-catenin has also been implicated in regulation of cell fates through asymmetric cell
division in the model organism C. elegans. Similarly to the Xenopus oocytes, this is
essentially the result of non-equal distribution of Dsh, Frizzled, axin and APC in the
cytoplasm of the mother cell.[40]

Stem cell renewal

One of the most important results of Wnt signaling and the elevated level of beta-catenin in
certain cell types is the maintenance of pluripotency.[36] In other cell types and developmental
stages, β-catenin may promote differentiation, especially towards mesodermal cell lineages.

Epithelial-to-mesenchymal transition
Beta-catenin also acts as a morphogen in later stages of embryonic development. Together
with TGF-β, an important role of β-catenin is to induce a morphogenic change in epithelial
cells. It induces them to abandon their tight adhesion and assume a more mobile and loosely
associated mesenchymal phenotype. During this process, epithelial cells lose expression of
proteins like E-cadherin, Zonula occludens 1 (ZO1), and cytokeratin. At the same time they
turn on the expression of vimentin, alpha smooth muscle actin (ACTA2), and fibroblast-
specific protein 1 (FSP1). They also produce extracellular matrix components, such as type I
collagen and fibronectin. Aberrant activation of the Wnt pathway has been implicated in
pathological processes such as fibrosis and cancer.[41] In cardiac muscle development, beta-
catenin performs a biphasic role. Initially, the activation of Wnt/beta-catenin is essential for
committing mesenchymal cells to a cardiac lineage; however, in later stages of development,
the downregulation of beta-catenin is required.[42][43][44]

Involvement in cardiac physiology

In cardiac muscle, beta-catenin forms a complex with N-cadherin at adherens junctions

within intercalated disc structures, which are responsible for electrical and mechanical
coupling of adjacent cardiac cells. Studies in a model of adult rat ventricular cardiomyocytes
have shown that the appearance and distribution of beta-catenin is spatio-temporally
regulated during the redifferentiation of these cells in culture. Specifically, beta-catenin is
part of a distinct complex with N-cadherin and alpha-catenin, which is abundant at adherens
junctions in early stages following cardiomyocyte isolation for the reformation of cell-cell
contacts.[45] It has been shown that beta-catenin forms a complex with emerin in
cardiomyocytes at adherens junctions within intercalated discs; and this interaction is
dependent on the presence of GSK 3-beta phosphorylation sites on beta-catenin. Knocking
out emerin significantly altred beta-catenin localization and the overall intercalated disc
architecture, which resembled a dilated cardiomyopathy phenotype.[46]

In animal models of cardiac disease, functions of beta-catenin have been unveiled. In a

guinea pig model of aortic stenosis and left ventricular hypertrophy, beta-catenin was shown
to change subcellular localization from intercalated discs to the cytosol, despite no change in
the overall cellular abundance of beta-catenin. vinculin showed a similar profile of change.
N-cadherin showed no change, and there was no compensatory upregulation of plakoglobin
at intercalated discs in the absence of beta-catenin.[47] In a hamster model of cardiomyopathy
and heart failure, cell-cell adhesions were irregular and disorganized, and expression levels of
adherens junction/intercalated disc and nuclear pools of beta-catenin were decreased.[48]
These data suggest that a loss of beta-catenin may play a role in the diseased intercalated
discs that have been associated with cardiac muscle hypertrophy and heart failure. In a rat
model of myocardial infarction, adenoviral gene transfer of nonphosphorylatable,
constitutively-active beta-catenin decreased MI size, activated the cell cycle, and reduced the
amount of apoptosis in cardiomyocytes and cardiac myofibroblasts. This finding was
coordinate with enhanced expression of pro-survival proteins, survivin and Bcl-2, and
vascular endothelial growth factor while promoting the differentiation of cardiac fibroblasts
into myofibroblasts. These findings suggest that beta-catenin can promote the regeneration
and healing process following myocardial infarction.[49] In a spontaneously-hypertensive
heart failure rat model, investigators detected a shuttling of beta-catenin from the intercalated
disc/sarcolemma to the nucleus, evidenced by a reduction of beta-catenin expression in the
membrane protein fraction and an increase in the nuclear fraction. Additionally, they found a
weakening in the association between glycogen synthase kinase-3β and beta-catenin, which
may indicate altered protein stability. Overall, results suggest that an enhanced nuclear
localization of beta-catenin may be important in the progression of cardiac hypertrophy.[50]

Regarding the mechanistic role of beta-catenin in cardiac hypertrophy, transgenic mouse

studies have shown somewhat conflicting results regarding whether upregulation of beta-
catenin is beneficial or detrimental.[51][52][53] A recent study using a conditional knockout
mouse that either lacked beta-catenin altogether or expressed a non-degradable form of beta-
catenin in cardiomyocytes reconciled a potential reason for these discrepancies. There
appears to be strict control over the subcellular localization of beta-catenin in cardiac muscle.
Mice lacking beta-catenin had no overt phenotype in the left ventricular myocardium;
however, mice harboring a stabilized form of beta-catenin developed dilated cardiomyopathy,
suggesting that the temporal regulation of beta-catenin by protein degradation mechanisms is
critical for normal functioning of beta-catenin in cardiac cells.[54] In a mouse model harboring
knockout of a desmosomal protein, plakoglobin, implicated in arrhythmogenic right
ventricular cardiomyopathy, the stabilization of beta-catenin was also enhanced, presumably
to compensate for the loss of its plakogloblin homolog. These changes were coordinate with
Akt activation and glycogen synthase kinase 3β inhibition, suggesting once again that the
abnormal stabilization of beta-catenin may be involved in the development of
cardiomyopathy.[55] Further studies employing a double knockout of plakoglobin and beta-
catenin showed that the double knockout developed cardiomyopathy, fibrosis and
arrhythmias resulting in sudden cardiac death. Intercalated disc architecture was severely
impaired and connexin 43-resident gap junctions were markedly reduced. Electrocardiogram
measurements captured spontaneous lethal ventricular arrhythmias in the double transgenic
animals, suggesting that the two catenins—beta-catenin and plakoglobin are critical and
idispensible for mechanoelectrical coupling in cardiomyocytes.[56]

Clinical significance
Role in depression

Whether or not a given individual’s brain can deal effectively with stress, and thus their
susceptibility to depression, depends on the beta-catenin in each person’s brain, according to
a study conducted at the Icahn School of Medicine at Mount Sinai and published November
12, 2014 in the journal Nature.[57]

Role in cardiac disease

Altered expression profiles in beta-catenin have been associated with dilated cardiomyopathy
in humans. Beta-catenin upregulation of expression has generally been observed in patients
with dilated cardiomyopathy.[58] In a particular study, patients with end-stage dilated
cardiomyopathy showed almost doubled estrogen receptor alpha (ER-alpha) mRNA and
protein levels, and the ER-alpha/beta-catenin interaction, present at intercalated discs of
control, non-diseased human hearts was lost, suggesting that the loss of this interaction at the
intercalated disc may play a role in the progression of heart failure.[59]

Involvement in cancer
Beta-catenin level regulation and cancer.

Beta-catenin is a proto-oncogene. Mutations of this gene are commonly found in a variety of

cancers: in primary hepatocellular carcinoma, colorectal cancer, ovarial carcinoma, breast
cancer, lung cancer and glioblastoma. It has been estimated that approximately 10% of all
tissue samples sequenced from all cancers display mutations in the CTNNB1 gene.[60] Most
of these mutations cluster on a tiny area of the N-terminal segment of β-catenin: the β-TrCP
binding motif. Loss-of-function mutations of this motif essentially make ubiquitinylation and
degradation of β-catenin impossible. It will cause β-catenin to translocate to the nucleus
without any external stimulus and continuously drive transcription of its target genes.
Increased nuclear β-catenin levels have also been noted in basal cell carcinoma (BCC),[61]
head and neck squamous cell carcinoma (HNSCC), prostate cancer (CaP),[62] pilomatrixoma
(PTR)[63] and medulloblastoma (MDB)[64] These observations may or may not implicate a
mutation in the β-catenin gene: other Wnt pathway components can also be faulty.

Similar mutations are also frequently seen in the β-catenin recruiting motifs of APC.
Hereditary loss-of-function mutations of APC cause a condition known as Familial
Adenomatous Polyposis. Affected individuals develop hundreds of polyps in their large
intestine. Most of these polyps are benign in nature, but they have the potential to transform
into deadly cancer as time progresses. Somatic mutations of APC in colorectal cancer are also
not uncommon.[65] Beta-catenin and APC are among the key genes (together with others, like
K-Ras and SMAD4) involved in colorectal cancer development. The potential of β-catenin to
change the previously epithelial phenotype of affected cells into an invasive, mesenchyme-
like type contributes greatly to metastasis formation.

As a therapeutic target

Due to its involvement in cancer development, inhibition of beta-catenin continues to receive

significant attention. But the targeting of the binding site on its armadillo domain is not the
simplest task, due to its extensive and relatively flat surface. However, for an efficient
inhibition, binding to smaller "hotspots" of this surface is sufficient. This way, a "stapled"
helical peptide derived from the natural β-catenin binding motif found in LEF1 was sufficient
for the complete inhibition of β-catenin dependent transcription. Recently, several small-
molecule compounds have also been developed to target the same, highly positively charged
area of the ARM domain (CGP049090, PKF118-310, PKF115-584 and ZTM000990). In
addition, β-catenin levels can also be influenced by targeting upstream components of the
Wnt pathway as well as the β-catenin destruction complex.[66] The additional N-terminal
binding pocket is also important for Wnt target gene activation (required for BCL9
recruitment). This site of the ARM domain can be pharmacologically targeted by carnosic
acid, for example.[67] That "auxiliary" site is another attractive target for drug development.[68]
Despite intensive preclinical research, no β-catenin inhibitors are available as therapeutic
agents yet. However, its function can be further examined by siRNA knockdown based on an
independent validation.[69]

Role in fetal alcohol syndrome

β-catenin destabilization by ethanol is one of two known pathways whereby alcohol exposure
induces fetal alcohol syndrome (the other is ethanol-induced folate deficiency). Ethanol leads
to β-catenin destabilization via a G-protein-dependent pathway, wherein activated
Phospholipase Cβ hydrolyzes phosphatidylinositol-(4,5)-bisphosphate to diacylglycerol and
inositol-(1,4,5)-trisphosphate. Soluble inositol-(1,4,5)-trisphosphate triggers calcium to be
released from the endoplasmic reticulum. This sudden increase in cytoplasmic calcium
activates Ca2+/calmodulin-dependent protein kinase (CaMKII). Activated CaMKII
destabilizes β-catenin via a poorly characterized mechanism, but which likely involves β-
catenin phosphorylation by CaMKII. The β-catenin transcriptional program (which is
required for normal neural crest cell development) is thereby suppressed, resulting in
premature neural crest cell apoptosis (cell death).[70]

Interactions
Beta-catenin has been shown to interact with:

 APC,[71][72][73][74][75][76][77][78]
 AXIN1,[79][80]
 Androgen receptor,[81][82][83][84][85][86]
 CBY1,[87]
 CDH1,[20][72][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108]
 CDH2,[45][109][110]
 CDH3,[107][111]
 CDK5R1,[112]
 CHUK,[113]
 CTNND1,[72][93]
 CTNNA1,[89][98][114][115][116]
 EGFR,[93][102][117]
 Emerin [118][119]
 ESR1 [59]
 FHL2,[120]
 GSK3B,[74][121]
 HER2/neu,[94][117][122]
 HNF4A,[85]
 IKK2,[113]
 LEF1,[123][124][125][126]
  MAGI1,[103]
 MUC1,[95][127][128][129][130][131][132]
 NR5A1,[133][134]
 PCAF,[135]
 PHF17,[136]
 Plakoglobin,[72][93]
 PTPN14,[137]
 PTPRF,[94][138]
 PTPRK (PTPkappa),[139]
 PTPRT (PTPrho),[140]
 PTPRU (PCP-2),[141][142][143]
 PSEN1,[144][145][146]
 PTK7[147]
 RuvB-like 1,[148]
 SMAD7,[123]
 SMARCA4[149]
 SLC9A3R1,[97]
 USP9X,[150] and
 VE-cadherin.[151][152]
 XIRP1 [153]

See also
 Catenin

References
1.

 "Human PubMed Reference:".

  "Mouse PubMed Reference:".
  Kraus C, Liehr T, Hülsken J, Behrens J, Birchmeier W, Grzeschik KH, Ballhausen WG
(Sep 1994). "Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region
implicated in tumor development". Genomics. 23 (1): 272–4. PMID 7829088.
doi:10.1006/geno.1994.1493.
  MacDonald BT, Tamai K, He X (Jul 2009). "Wnt/beta-catenin signaling: components,
mechanisms, and diseases". Developmental Cell. 17 (1): 9–26. PMC 2861485  .
PMID 19619488. doi:10.1016/j.devcel.2009.06.016.
  Peifer M, Rauskolb C, Williams M, Riggleman B, Wieschaus E (Apr 1991). "The
segment polarity gene armadillo interacts with the wingless signaling pathway in both
embryonic and adult pattern formation". Development. 111 (4): 1029–1043. PMID 1879348.
  Noordermeer J, Klingensmith J, Perrimon N, Nusse R (Jan 1994). "dishevelled and
armadillo act in the wingless signalling pathway in Drosophila". Nature. 367 (6458): 80–83.
PMID 7906389. doi:10.1038/367080a0.
  Peifer M, Berg S, Reynolds AB (Mar 1994). "A repeating amino acid motif shared by
proteins with diverse cellular roles". Cell. 76 (5): 789–91. PMID 7907279.
doi:10.1016/0092-8674(94)90353-0.
  Morin PJ (Dec 1999). "beta-catenin signaling and cancer". BioEssays. 21 (12): 1021–
30. PMID 10580987. doi:10.1002/(SICI)1521-1878(199912)22:1<1021::AID-
BIES6>3.0.CO;2-P.
  McCrea PD, Turck CW, Gumbiner B (Nov 1991). "A homolog of the armadillo protein
in Drosophila (plakoglobin) associated with E-cadherin". Science. 254 (5036): 1359–61.
PMID 1962194. doi:10.1126/science.1962194.
  Kemler R (Sep 1993). "From cadherins to catenins: cytoplasmic protein interactions and
regulation of cell adhesion". Trends in Genetics. 9 (9): 317–21. PMID 8236461.
doi:10.1016/0168-9525(93)90250-l.
  Gottardi CJ, Peifer M (Mar 2008). "Terminal regions of beta-catenin come into view".
Structure. 16 (3): 336–8. PMC 2329800  . PMID 18334207. doi:10.1016/j.str.2008.02.005.
  Xing Y, Takemaru K, Liu J, Berndt JD, Zheng JJ, Moon RT, Xu W (Mar 2008). "Crystal
structure of a full-length beta-catenin". Structure. 16 (3): 478–87. PMC 4267759  .
PMID 18334222. doi:10.1016/j.str.2007.12.021.
  Vleminckx K, Kemler R, Hecht A (Mar 1999). "The C-terminal transactivation domain of
beta-catenin is necessary and sufficient for signaling by the LEF-1/beta-catenin complex in
Xenopus laevis". Mechanisms of Development. 81 (1–2): 65–74. PMID 10330485.
doi:10.1016/s0925-4773(98)00225-1.
  Sadot E, Simcha I, Iwai K, Ciechanover A, Geiger B, Ben-Ze'ev A (Apr 2000).
"Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome
system". Oncogene. 19 (16): 1992–2001. PMID 10803460. doi:10.1038/sj.onc.1203519.
  Aktary Z, Pasdar M (2012). "Plakoglobin: role in tumorigenesis and metastasis".
International Journal of Cell Biology. 2012: 189521. PMC 3312339  . PMID 22481945.
doi:10.1155/2012/189521.
  Xu W, Kimelman D (Oct 2007). "Mechanistic insights from structural studies of beta-
catenin and its binding partners". Journal of Cell Science. 120 (Pt 19): 3337–44.
PMID 17881495. doi:10.1242/jcs.013771.
  Graham TA, Weaver C, Mao F, Kimelman D, Xu W (Dec 2000). "Crystal structure of a
beta-catenin/Tcf complex". Cell. 103 (6): 885–896. PMID 11136974. doi:10.1016/S0092-
8674(00)00192-6.
  Graham TA, Ferkey DM, Mao F, Kimelman D, Xu W (Dec 2001). "Tcf4 can specifically
recognize beta-catenin using alternative conformations". Nature Structural Biology. 8 (12):
1048–1052. PMID 11713475. doi:10.1038/nsb718.
  Poy F, Lepourcelet M, Shivdasani RA, Eck MJ (Dec 2001). "Structure of a human Tcf4-
beta-catenin complex". Nature Structural Biology. 8 (12): 1053–1057. PMID 11713476.
doi:10.1038/nsb720.
  Huber AH, Weis WI (May 2001). "The structure of the beta-catenin/E-cadherin complex
and the molecular basis of diverse ligand recognition by beta-catenin". Cell. 105 (3): 391–
402. PMID 11348595. doi:10.1016/S0092-8674(01)00330-0.
  Xing Y, Clements WK, Kimelman D, Xu W (Nov 2003). "Crystal structure of a beta-
catenin/axin complex suggests a mechanism for the beta-catenin destruction complex". Genes
& Development. 17 (22): 2753–64. PMC 280624  . PMID 14600025.
doi:10.1101/gad.1142603.
  Minde DP, Anvarian Z, Rüdiger SG, Maurice MM (22 August 2011). "Messing up
disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?"
(PDF). Molecular Cancer. 10 (1): 101. PMC 3170638  . PMID 21859464. doi:10.1186/1476-
4598-10-101.
  Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Züllig S,
Basler K (Apr 2002). "Wnt/wingless signaling requires BCL9/legless-mediated recruitment of
pygopus to the nuclear beta-catenin-TCF complex". Cell. 109 (1): 47–60. PMID 11955446.
doi:10.1016/S0092-8674(02)00679-7.
  Pokutta S, Weis WI (Mar 2000). "Structure of the dimerization and beta-catenin-binding
region of alpha-catenin". Molecular Cell. 5 (3): 533–43. PMID 10882138.
doi:10.1016/S1097-2765(00)80447-5.
  Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W (Oct 2006). "Crystal
structure of a beta-catenin/BCL9/Tcf4 complex". Molecular Cell. 24 (2): 293–300.
PMID 17052462. doi:10.1016/j.molcel.2006.09.001.
  Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M,
Birchmeier W (Sep 2004). "Essential role of BCL9-2 in the switch between beta-catenin's
adhesive and transcriptional functions". Genes & Development. 18 (18): 2225–30.
PMC 517514  . PMID 15371335. doi:10.1101/gad.317604.
  Liu J, Xing Y, Hinds TR, Zheng J, Xu W (Jun 2006). "The third 20 amino acid repeat is
the tightest binding site of APC for beta-catenin". Journal of Molecular Biology. 360 (1):
133–44. PMID 16753179. doi:10.1016/j.jmb.2006.04.064.
  Kimelman D, Xu W (Dec 2006). "beta-catenin destruction complex: insights and
questions from a structural perspective". Oncogene. 25 (57): 7482–91. PMID 17143292.
doi:10.1038/sj.onc.1210055.
  Fiedler M, Mendoza-Topaz C, Rutherford TJ, Mieszczanek J, Bienz M (Feb 2011).
"Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with
its function in down-regulating β-catenin". Proceedings of the National Academy of Sciences
of the United States of America. 108 (5): 1937–42. PMC 3033301  . PMID 21245303.
doi:10.1073/pnas.1017063108.
  Metcalfe C, Bienz M (Nov 2011). "Inhibition of GSK3 by Wnt signalling--two
contrasting models". Journal of Cell Science. 124 (Pt 21): 3537–44. PMID 22083140.
doi:10.1242/jcs.091991.
  Brembeck FH, Rosário M, Birchmeier W (Feb 2006). "Balancing cell adhesion and Wnt
signaling, the key role of beta-catenin". Current Opinion in Genetics & Development. 16 (1):
51–9. PMID 16377174. doi:10.1016/j.gde.2005.12.007.
  "Entrez Gene: catenin (cadherin-associated protein)".
  Nelson WJ (Apr 2008). "Regulation of cell-cell adhesion by the cadherin-catenin
complex". Biochemical Society Transactions. 36 (Pt 2): 149–55. PMC 3368607  .
PMID 18363555. doi:10.1042/BST0360149.
  Bienz M (Jan 2005). "beta-Catenin: a pivot between cell adhesion and Wnt signalling".
Current Biology. 15 (2): R64–7. PMID 15668160. doi:10.1016/j.cub.2004.12.058.
  Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R (Nov 1995). "Lack
of beta-catenin affects mouse development at gastrulation". Development. 121 (11): 3529–37.
PMID 8582267.
  Sokol SY (Oct 2011). "Maintaining embryonic stem cell pluripotency with Wnt
signaling". Development. 138 (20): 4341–50. PMC 3177306  . PMID 21903672.
doi:10.1242/dev.066209.
  Schneider S, Steinbeisser H, Warga RM, Hausen P (Jul 1996). "Beta-catenin
translocation into nuclei demarcates the dorsalizing centers in frog and fish embryos".
Mechanisms of Development. 57 (2): 191–8. PMID 8843396. doi:10.1016/0925-
4773(96)00546-1.
  Larabell CA, Torres M, Rowning BA, Yost C, Miller JR, Wu M, Kimelman D, Moon RT
(Mar 1997). "Establishment of the dorso-ventral axis in Xenopus embryos is presaged by
early asymmetries in beta-catenin that are modulated by the Wnt signaling pathway". The
Journal of Cell Biology. 136 (5): 1123–36. PMC 2132470  . PMID 9060476.
doi:10.1083/jcb.136.5.1123.
  Kelly GM, Erezyilmaz DF, Moon RT (Oct 1995). "Induction of a secondary embryonic
axis in zebrafish occurs following the overexpression of beta-catenin". Mechanisms of
Development. 53 (2): 261–73. PMID 8562427. doi:10.1016/0925-4773(95)00442-4.
  Sawa H (2012). "Control of cell polarity and asymmetric division in C. elegans".
Current Topics in Developmental Biology. 101: 55–76. PMID 23140625. doi:10.1016/B978-
0-12-394592-1.00003-X.
  Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, Zhao Y, Harris DC, Zheng G (2011). "E-
cadherin/β-catenin complex and the epithelial barrier". Journal of Biomedicine &
Biotechnology. 2011: 567305. PMC 3191826  . PMID 22007144. doi:10.1155/2011/567305.
  Zelarayan L, Gehrke C, Bergmann MW (Sep 2007). "Role of beta-catenin in adult
cardiac remodeling". Cell Cycle. 6 (17): 2120–6. PMID 17786052.
doi:10.4161/cc.6.17.4632.
  Lickert H, Kutsch S, Kanzler B, Tamai Y, Taketo MM, Kemler R (Aug 2002). "Formation
of multiple hearts in mice following deletion of beta-catenin in the embryonic endoderm".
Developmental Cell. 3 (2): 171–81. PMID 12194849. doi:10.1016/s1534-5807(02)00206-x.
  Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R (Nov 1995). "Lack
of beta-catenin affects mouse development at gastrulation". Development. 121 (11): 3529–37.
PMID 8582267.
  Hertig CM, Butz S, Koch S, Eppenberger-Eberhardt M, Kemler R, Eppenberger HM
(Jan 1996). "N-cadherin in adult rat cardiomyocytes in culture. II. Spatio-temporal
appearance of proteins involved in cell-cell contact and communication. Formation of two
distinct N-cadherin/catenin complexes". Journal of Cell Science. 109 (1): 11–20.
PMID 8834786.
  Wheeler MA, Warley A, Roberts RG, Ehler E, Ellis JA (Mar 2010). "Identification of an
emerin-beta-catenin complex in the heart important for intercalated disc architecture and
beta-catenin localisation". Cellular and Molecular Life Sciences. 67 (5): 781–96.
PMID 19997769. doi:10.1007/s00018-009-0219-8.
  Wang X, Gerdes AM (Feb 1999). "Chronic pressure overload cardiac hypertrophy and
failure in guinea pigs: III. Intercalated disc remodeling". Journal of Molecular and Cellular
Cardiology. 31 (2): 333–43. PMID 10093046. doi:10.1006/jmcc.1998.0886.
  Yoshida M, Ohkusa T, Nakashima T, Takanari H, Yano M, Takemura G, Honjo H,
Kodama I, Mizukami Y, Matsuzaki M (Oct 2011). "Alterations in adhesion junction precede
gap junction remodelling during the development of heart failure in cardiomyopathic
hamsters". Cardiovascular Research. 92 (1): 95–105. PMID 21693625.
doi:10.1093/cvr/cvr182.
  Hahn JY, Cho HJ, Bae JW, Yuk HS, Kim KI, Park KW, Koo BK, Chae IH, Shin CS, Oh
BH, Choi YS, Park YB, Kim HS (Oct 2006). "Beta-catenin overexpression reduces
myocardial infarct size through differential effects on cardiomyocytes and cardiac
fibroblasts". The Journal of Biological Chemistry. 281 (41): 30979–89. PMID 16920707.
doi:10.1074/jbc.M603916200.
  Zheng Q, Chen P, Xu Z, Li F, Yi XP (Oct 2013). "Expression and redistribution of β-
catenin in the cardiac myocytes of left ventricle of spontaneously hypertensive rat". Journal
of Molecular Histology. 44 (5): 565–73. PMID 23591738. doi:10.1007/s10735-013-9507-6.
  Baurand A, Zelarayan L, Betney R, Gehrke C, Dunger S, Noack C, Busjahn A, Huelsken
J, Taketo MM, Birchmeier W, Dietz R, Bergmann MW (May 2007). "Beta-catenin
downregulation is required for adaptive cardiac remodeling". Circulation Research. 100 (9):
1353–62. PMID 17413044. doi:10.1161/01.RES.0000266605.63681.5a.
  Chen X, Shevtsov SP, Hsich E, Cui L, Haq S, Aronovitz M, Kerkelä R, Molkentin JD,
Liao R, Salomon RN, Patten R, Force T (Jun 2006). "The beta-catenin/T-cell
factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-
induced cardiac hypertrophy". Molecular and Cellular Biology. 26 (12): 4462–73.
PMC 1489123  . PMID 16738313. doi:10.1128/MCB.02157-05.
  Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B, Woodgett J, Kilter
H, Force T (Apr 2003). "Stabilization of beta-catenin by a Wnt-independent mechanism
regulates cardiomyocyte growth". Proceedings of the National Academy of Sciences of the
United States of America. 100 (8): 4610–5. PMC 153603  . PMID 12668767.
doi:10.1073/pnas.0835895100.
  Hirschy A, Croquelois A, Perriard E, Schoenauer R, Agarkova I, Hoerstrup SP, Taketo
MM, Pedrazzini T, Perriard JC, Ehler E (Sep 2010). "Stabilised beta-catenin in postnatal
ventricular myocardium leads to dilated cardiomyopathy and premature death". Basic
Research in Cardiology. 105 (5): 597–608. PMID 20376467. doi:10.1007/s00395-010-0101-
8.
  Li J, Swope D, Raess N, Cheng L, Muller EJ, Radice GL (Mar 2011). "Cardiac tissue-
restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of
{beta}-catenin signaling". Molecular and Cellular Biology. 31 (6): 1134–44. PMC 3067899 
. PMID 21245375. doi:10.1128/MCB.01025-10.
  Swope D, Cheng L, Gao E, Li J, Radice GL (Mar 2012). "Loss of cadherin-binding
proteins β-catenin and plakoglobin in the heart leads to gap junction remodeling and
arrhythmogenesis". Molecular and Cellular Biology. 32 (6): 1056–67. PMC 3295003  .
PMID 22252313. doi:10.1128/MCB.06188-11.
  Dias, Caroline; Feng, Jian; Sun, Haosheng; Shao, Ning yi; Mazei-Robison, Michelle S.;
Damez-Werno, Diane; Scobie, Kimberly; Bagot, Rosemary; LaBonté, Benoit (2014). "β-
catenin mediates stress resilience through Dicer1/microRNA regulation". Nature. 516: 51–5.
PMC 4257892  . PMID 25383518. doi:10.1038/nature13976.
  Perriard JC, Hirschy A, Ehler E (Jan 2003). "Dilated cardiomyopathy: a disease of the
intercalated disc?". Trends in Cardiovascular Medicine. 13 (1): 30–8. PMID 12554098.
doi:10.1016/s1050-1738(02)00209-8.
  Mahmoodzadeh S, Eder S, Nordmeyer J, Ehler E, Huber O, Martus P, Weiske J, Pregla
R, Hetzer R, Regitz-Zagrosek V (May 2006). "Estrogen receptor alpha up-regulation and
redistribution in human heart failure". FASEB Journal. 20 (7): 926–34. PMID 16675850.
doi:10.1096/fj.05-5148com.
  Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung
K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA (Jan 2011). "COSMIC:
mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer". Nucleic
Acids Research. 39 (Database issue): D945–50. PMC 3013785  . PMID 20952405.
doi:10.1093/nar/gkq929.
  Saldanha G, Ghura V, Potter L, Fletcher A (Jul 2004). "Nuclear beta-catenin in basal
cell carcinoma correlates with increased proliferation". The British Journal of Dermatology.
151 (1): 157–64. PMID 15270885. doi:10.1111/j.1365-2133.2004.06048.x.
  Kypta RM, Waxman J (Aug 2012). "Wnt/β-catenin signalling in prostate cancer". Nature
Reviews. Urology. 9 (8): 418–428. PMID 22710668. doi:10.1038/nrurol.2012.116.
  Hassanein AM, Glanz SM, Kessler HP, Eskin TA, Liu C (2003). "β-Catenin Is Expressed
Aberrantly in Tumors Expressing Shadow Cells". Anatomic Pathology. 120: 732–6.
PMID 14608900. doi:10.1309/EALEG7LD6W7167PX.
  Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD,
Clifford SC (Nov 2005). "beta-Catenin status predicts a favorable outcome in childhood
medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour
Committee". Journal of Clinical Oncology. 23 (31): 7951–7. PMID 16258095.
doi:10.1200/JCO.2005.01.5479.
  Kobayashi M, Honma T, Matsuda Y, Suzuki Y, Narisawa R, Ajioka Y, Asakura H (May
2000). "Nuclear translocation of beta-catenin in colorectal cancer". British Journal of
Cancer. 82 (10): 1689–1693. PMC 2374509  . PMID 10817505.
doi:10.1054/bjoc.1999.1112.
  Voronkov A, Krauss S (2013). "Wnt/beta-catenin signaling and small molecule
inhibitors". Current Pharmaceutical Design. 19 (4): 634–64. PMC 3529405  .
PMID 23016862. doi:10.2174/1381612811306040634.
  de la Roche M, Rutherford TJ, Gupta D, Veprintsev DB, Saxty B, Freund SM, Bienz M
(2012). "An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is
required for its inhibition by carnosic acid". Nature Communications. 3 (2): 680.
PMC 3293410  . PMID 22353711. doi:10.1038/ncomms1680.
  Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, Lemieux M, Carrasco DE,
Ryan J, Horst D, Fulciniti M, Munshi NC, Xu W, Kung AL, Shivdasani RA, Walensky LD,
Carrasco DR (Aug 2012). "Targeted disruption of the BCL9/β-catenin complex inhibits
oncogenic Wnt signaling". Science Translational Medicine. 4 (148): 148ra117.
PMC 3631420  . PMID 22914623. doi:10.1126/scitranslmed.3003808.
  Munkácsy, Gyöngyi; Sztupinszki, Zsófia; Herman, Péter; Bán, Bence; Pénzváltó, Zsófia;
Szarvas, Nóra; Győrffy, Balázs (2016-01-01). "Validation of RNAi Silencing Efficiency Using
Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments".
Molecular Therapy - Nucleic Acids. 5. ISSN 2162-2531. PMC 5056990  . PMID 27673562.
doi:10.1038/mtna.2016.66.
  Flentke, G. R.; Garic, A; Amberger, E; Hernandez, M; Smith, S. M. (2011). "Calcium-
mediated repression of β-catenin and its transcriptional signaling mediates neural crest cell
death in an avian model of fetal alcohol syndrome". Birth Defects Research Part A: Clinical
and Molecular Teratology. 91 (7): 591–602. PMC 4827605  . PMID 21630427.
doi:10.1002/bdra.20833.
  Su LK, Vogelstein B, Kinzler KW (Dec 1993). "Association of the APC tumor suppressor
protein with catenins". Science. 262 (5140): 1734–7. PMID 8259519.
doi:10.1126/science.8259519.
  Kucerová D, Sloncová E, Tuhácková Z, Vojtechová M, Sovová V (Dec 2001).
"Expression and interaction of different catenins in colorectal carcinoma cells".
International Journal of Molecular Medicine. 8 (6): 695–8. PMID 11712088.
doi:10.3892/ijmm.8.6.695.
  Tickenbrock L, Kössmeier K, Rehmann H, Herrmann C, Müller O (Mar 2003).
"Differences between the interaction of beta-catenin with non-phosphorylated and single-
mimicked phosphorylated 20-amino acid residue repeats of the APC protein". Journal of
Molecular Biology. 327 (2): 359–67. PMID 12628243. doi:10.1016/S0022-2836(03)00144-X.
  Davies G, Jiang WG, Mason MD (Apr 2001). "The interaction between beta-catenin,
GSK3beta and APC after motogen induced cell-cell dissociation, and their involvement in
signal transduction pathways in prostate cancer". International Journal of Oncology. 18 (4):
843–7. PMID 11251183. doi:10.3892/ijo.18.4.843.
  Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP (Sep 2001). "Pin1 regulates turnover and
subcellular localization of beta-catenin by inhibiting its interaction with APC". Nature Cell
Biology. 3 (9): 793–801. PMID 11533658. doi:10.1038/ncb0901-793.
  Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y (Apr 2002). "Association and
regulation of casein kinase 2 activity by adenomatous polyposis coli protein". Proceedings of
the National Academy of Sciences of the United States of America. 99 (9): 5959–64.
PMC 122884  . PMID 11972058. doi:10.1073/pnas.092143199.
  Satoh K, Yanai H, Senda T, Kohu K, Nakamura T, Okumura N, Matsumine A, Kobayashi
S, Toyoshima K, Akiyama T (Jun 1997). "DAP-1, a novel protein that interacts with the
guanylate kinase-like domains of hDLG and PSD-95". Genes to Cells. 2 (6): 415–24.
PMID 9286858. doi:10.1046/j.1365-2443.1997.1310329.x.
  Eklof Spink K, Fridman SG, Weis WI (Nov 2001). "Molecular mechanisms of beta-
catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-
catenin complex". The EMBO Journal. 20 (22): 6203–12. PMC 125720  . PMID 11707392.
doi:10.1093/emboj/20.22.6203.
  Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, Akiyama T
(Jun 1998). "Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin,
GSK-3beta and APC and reduces the beta-catenin level". Genes to Cells. 3 (6): 395–403.
PMID 9734785. doi:10.1046/j.1365-2443.1998.00198.x.
  Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH (Jun 2003).
"Regulation of the Wnt signaling pathway by disabled-2 (Dab2)". The EMBO Journal. 22
(12): 3084–94. PMC 162138  . PMID 12805222. doi:10.1093/emboj/cdg286.
  Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z (Mar 2002). "Linking
beta-catenin to androgen-signaling pathway". The Journal of Biological Chemistry. 277
(13): 11336–44. PMID 11792709. doi:10.1074/jbc.M111962200.
  Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP (Oct
2004). "Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates
with ligand-stimulated growth of prostate cancer cells". Molecular Endocrinology. 18 (10):
2388–401. PMID 15256534. doi:10.1210/me.2003-0436.
  Song LN, Coghlan M, Gelmann EP (Jan 2004). "Antiandrogen effects of mifepristone on
coactivator and corepressor interactions with the androgen receptor". Molecular
Endocrinology. 18 (1): 70–85. PMID 14593076. doi:10.1210/me.2003-0189.
  Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP (Aug 2003). "A direct
beta-catenin-independent interaction between androgen receptor and T cell factor 4". The
Journal of Biological Chemistry. 278 (33): 30828–34. PMID 12799378.
doi:10.1074/jbc.M301208200.
  Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC (Aug 2003). "Functional
localization and competition between the androgen receptor and T-cell factor for nuclear
beta-catenin: a means for inhibition of the Tcf signaling axis". Oncogene. 22 (36): 5602–13.
PMID 12944908. doi:10.1038/sj.onc.1206802.
  Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME (Jun
2002). "Liganded androgen receptor interaction with beta-catenin: nuclear co-localization
and modulation of transcriptional activity in neuronal cells". The Journal of Biological
Chemistry. 277 (23): 20702–10. PMID 11916967. doi:10.1074/jbc.M200545200.
  Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT (Apr 2003).
"Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway".
Nature. 422 (6934): 905–9. PMID 12712206. doi:10.1038/nature01570.
  Davies G, Jiang WG, Mason MD (Apr 2001). "HGF/SF modifies the interaction between
its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells".
International Journal of Molecular Medicine. 7 (4): 385–8. PMID 11254878.
doi:10.3892/ijmm.7.4.385.
  Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K, Nagafuchi A, Tsukita S,
Shibamoto S, Ito F (Dec 1994). "A truncated beta-catenin disrupts the interaction between E-
cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer
cell lines". Cancer Research. 54 (23): 6282–7. PMID 7954478.
  Hazan RB, Kang L, Roe S, Borgen PI, Rimm DL (Dec 1997). "Vinculin is associated
with the E-cadherin adhesion complex". The Journal of Biological Chemistry. 272 (51):
32448–53. PMID 9405455. doi:10.1074/jbc.272.51.32448.
  Kinch MS, Clark GJ, Der CJ, Burridge K (Jul 1995). "Tyrosine phosphorylation
regulates the adhesions of ras-transformed breast epithelia". The Journal of Cell Biology.
130 (2): 461–71. PMC 2199929  . PMID 7542250. doi:10.1083/jcb.130.2.461.
  Jiang MC, Liao CF, Tai CC (Jun 2002). "CAS/CSE 1 stimulates E-cadhrin-dependent
cell polarity in HT-29 human colon epithelial cells". Biochemical and Biophysical Research
Communications. 294 (4): 900–5. PMID 12061792. doi:10.1016/S0006-291X(02)00551-X.
  Hazan RB, Norton L (Apr 1998). "The epidermal growth factor receptor modulates the
interaction of E-cadherin with the actin cytoskeleton". The Journal of Biological Chemistry.
273 (15): 9078–84. PMID 9535896. doi:10.1074/jbc.273.15.9078.
  Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M,
Neckers LM (Feb 2001). "Geldanamycin abrogates ErbB2 association with proteasome-
resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and
decreases beta-catenin-sensitive transcription". Cancer Research. 61 (4): 1671–7.
PMID 11245482.
  Li Y, Bharti A, Chen D, Gong J, Kufe D (Dec 1998). "Interaction of glycogen synthase
kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin".
Molecular and Cellular Biology. 18 (12): 7216–24. PMC 109303  . PMID 9819408.
doi:10.1128/mcb.18.12.7216.
  Wendeler MW, Praus M, Jung R, Hecking M, Metzig C, Gessner R (Apr 2004). "Ksp-
cadherin is a functional cell-cell adhesion molecule related to LI-cadherin". Experimental
Cell Research. 294 (2): 345–55. PMID 15023525. doi:10.1016/j.yexcr.2003.11.022.
  Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S (Jul 2003). "EBP50, a beta-
catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular
carcinoma". Hepatology. 38 (1): 178–86. PMID 12830000. doi:10.1053/jhep.2003.50270.
  Piedra J, Miravet S, Castaño J, Pálmer HG, Heisterkamp N, García de Herreros A,
Duñach M (Apr 2003). "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-
catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction". Molecular
and Cellular Biology. 23 (7): 2287–97. PMC 150740  . PMID 12640114.
doi:10.1128/MCB.23.7.2287-2297.2003.
  Kang JS, Feinleib JL, Knox S, Ketteringham MA, Krauss RS (Apr 2003). "Promyogenic
members of the Ig and cadherin families associate to positively regulate differentiation".
Proceedings of the National Academy of Sciences of the United States of America. 100 (7):
3989–94. PMC 153035  . PMID 12634428. doi:10.1073/pnas.0736565100.
  Oneyama C, Nakano H, Sharma SV (Mar 2002). "UCS15A, a novel small molecule, SH3
domain-mediated protein-protein interaction blocking drug". Oncogene. 21 (13): 2037–50.
PMID 11960376. doi:10.1038/sj.onc.1205271.
  Navarro P, Lozano E, Cano A (Aug 1993). "Expression of E- or P-cadherin is not
sufficient to modify the morphology and the tumorigenic behavior of murine spindle
carcinoma cells. Possible involvement of plakoglobin". Journal of Cell Science. 105 (4):
923–34. PMID 8227214.
  Takahashi K, Suzuki K, Tsukatani Y (Jul 1997). "Induction of tyrosine phosphorylation
and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at
confluence". Oncogene. 15 (1): 71–8. PMID 9233779. doi:10.1038/sj.onc.1201160.
  Dobrosotskaya IY, James GL (Apr 2000). "MAGI-1 interacts with beta-catenin and is
associated with cell-cell adhesion structures". Biochemical and Biophysical Research
Communications. 270 (3): 903–9. PMID 10772923. doi:10.1006/bbrc.2000.2471.
  Geng L, Burrow CR, Li HP, Wilson PD (Dec 2000). "Modification of the composition of
polycystin-1 multiprotein complexes by calcium and tyrosine phosphorylation". Biochimica et
Biophysica Acta. 1535 (1): 21–35. PMID 11113628. doi:10.1016/S0925-4439(00)00079-X.
  Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, Johnson KR,
Wheelock MJ, Matsuyoshi N, Takeichi M (Mar 1995). "Association of p120, a tyrosine kinase
substrate, with E-cadherin/catenin complexes". The Journal of Cell Biology. 128 (5): 949–
57. PMC 2120395  . PMID 7876318. doi:10.1083/jcb.128.5.949.
  Rao RK, Basuroy S, Rao VU, Karnaky Jr KJ, Gupta A (Dec 2002). "Tyrosine
phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes
from the cytoskeleton by oxidative stress". The Biochemical Journal. 368 (Pt 2): 471–81.
PMC 1222996  . PMID 12169098. doi:10.1042/BJ20011804.
  Schmeiser K, Grand RJ (Apr 1999). "The fate of E- and P-cadherin during the early
stages of apoptosis". Cell Death and Differentiation. 6 (4): 377–86. PMID 10381631.
doi:10.1038/sj.cdd.4400504.
  Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, French DM (Jul 2008). "Inhibition of
fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling".
Cancer Research. 68 (13): 5086–95. PMID 18593907. doi:10.1158/0008-5472.CAN-07-
2325.
  Straub BK, Boda J, Kuhn C, Schnoelzer M, Korf U, Kempf T, Spring H, Hatzfeld M,
Franke WW (Dec 2003). "A novel cell-cell junction system: the cortex adhaerens mosaic of
lens fiber cells". Journal of Cell Science. 116 (Pt 24): 4985–95. PMID 14625392.
doi:10.1242/jcs.00815.
  Wahl JK, Kim YJ, Cullen JM, Johnson KR, Wheelock MJ (May 2003). "N-cadherin-
catenin complexes form prior to cleavage of the proregion and transport to the plasma
membrane". The Journal of Biological Chemistry. 278 (19): 17269–76. PMID 12604612.
doi:10.1074/jbc.M211452200.
  Klingelhöfer J, Troyanovsky RB, Laur OY, Troyanovsky S (Aug 2000). "Amino-terminal
domain of classic cadherins determines the specificity of the adhesive interactions". Journal
of Cell Science. 113 (16): 2829–36. PMID 10910767.
  Kesavapany S, Lau KF, McLoughlin DM, Brownlees J, Ackerley S, Leigh PN, Shaw CE,
Miller CC (Jan 2001). "p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-
catenin/presenilin-1 interaction". The European Journal of Neuroscience. 13 (2): 241–7.
PMID 11168528. doi:10.1046/j.1460-9568.2001.01376.x.
  Lamberti C, Lin KM, Yamamoto Y, Verma U, Verma IM, Byers S, Gaynor RB (Nov
2001). "Regulation of beta-catenin function by the IkappaB kinases". The Journal of
Biological Chemistry. 276 (45): 42276–86. PMID 11527961. doi:10.1074/jbc.M104227200.
  Roe S, Koslov ER, Rimm DL (Jun 1998). "A mutation in alpha-catenin disrupts adhesion
in clone A cells without perturbing its actin and beta-catenin binding activity". Cell Adhesion
and Communication. 5 (4): 283–96. PMID 9762469. doi:10.3109/15419069809040298.
  Aberle H, Butz S, Stappert J, Weissig H, Kemler R, Hoschuetzky H (Dec 1994).
"Assembly of the cadherin-catenin complex in vitro with recombinant proteins". Journal of
Cell Science. 107 (12): 3655–63. PMID 7706414.
  Reuver SM, Garner CC (Apr 1998). "E-cadherin mediated cell adhesion recruits SAP97
into the cortical cytoskeleton". Journal of Cell Science. 111 (8): 1071–80. PMID 9512503.
  Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ (Jun
2002). "ErbB-beta-catenin complexes are associated with human infiltrating ductal breast
and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic
carcinomas". The Journal of Biological Chemistry. 277 (25): 22692–8. PMID 11950845.
doi:10.1074/jbc.M201975200.
  Cartegni L, di Barletta MR, Barresi R, Squarzoni S, Sabatelli P, Maraldi N, Mora M, Di
Blasi C, Cornelio F, Merlini L, Villa A, Cobianchi F, Toniolo D (Dec 1997). "Heart-specific
localization of emerin: new insights into Emery–Dreifuss muscular dystrophy". Human
Molecular Genetics. 6 (13): 2257–64. PMID 9361031. doi:10.1093/hmg/6.13.2257.
  Markiewicz E, Tilgner K, Barker N, van de Wetering M, Clevers H, Dorobek M,
Hausmanowa-Petrusewicz I, Ramaekers FC, Broers JL, Blankesteijn WM, Salpingidou G,
Wilson RG, Ellis JA, Hutchison CJ (Jul 2006). "The inner nuclear membrane protein emerin
regulates beta-catenin activity by restricting its accumulation in the nucleus". The EMBO
Journal. 25 (14): 3275–85. PMC 1523183  . PMID 16858403.
doi:10.1038/sj.emboj.7601230.
  Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, Prieur X, Flajolet M, Prigent
S, Buendia MA (Feb 2003). "Identification of the LIM protein FHL2 as a coactivator of beta-
catenin". The Journal of Biological Chemistry. 278 (7): 5188–94. PMID 12466281.
doi:10.1074/jbc.M207216200.
  Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M, Kikuchi A (Jun 1999). "DIX
domains of Dvl and axin are necessary for protein interactions and their ability to regulate
beta-catenin stability". Molecular and Cellular Biology. 19 (6): 4414–22. PMC 104400  .
PMID 10330181. doi:10.1128/mcb.19.6.4414.
  Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S (Mar
1995). "c-erbB-2 gene product directly associates with beta-catenin and plakoglobin".
Biochemical and Biophysical Research Communications. 208 (3): 1067–72. PMID 7702605.
doi:10.1006/bbrc.1995.1443.
  Edlund S, Lee SY, Grimsby S, Zhang S, Aspenström P, Heldin CH, Landström M (Feb
2005). "Interaction between Smad7 and beta-catenin: importance for transforming growth
factor beta-induced apoptosis". Molecular and Cellular Biology. 25 (4): 1475–88.
PMC 548008  . PMID 15684397. doi:10.1128/MCB.25.4.1475-1488.2005.
  Grueneberg DA, Pablo L, Hu KQ, August P, Weng Z, Papkoff J (Jun 2003). "A
functional screen in human cells identifies UBF2 as an RNA polymerase II transcription
factor that enhances the beta-catenin signaling pathway". Molecular and Cellular Biology.
23 (11): 3936–50. PMC 155208  . PMID 12748295. doi:10.1128/MCB.23.11.3936-
3950.2003.
  Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W
(Aug 1996). "Functional interaction of beta-catenin with the transcription factor LEF-1".
Nature. 382 (6592): 638–42. PMID 8757136. doi:10.1038/382638a0.
  Labbé E, Letamendia A, Attisano L (Jul 2000). "Association of Smads with lymphoid
enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the
transforming growth factor-beta and wnt pathways". Proceedings of the National Academy of
Sciences of the United States of America. 97 (15): 8358–63. PMC 26952  . PMID 10890911.
doi:10.1073/pnas.150152697.
  Yamamoto M, Bharti A, Li Y, Kufe D (May 1997). "Interaction of the DF3/MUC1 breast
carcinoma-associated antigen and beta-catenin in cell adhesion". The Journal of Biological
Chemistry. 272 (19): 12492–4. PMID 9139698. doi:10.1074/jbc.272.19.12492.
  Durum SK, Aiello FB (2003). "Interleukin-7 induces MUC1". Cancer Biology &
Therapy. 2 (2): 194–5. PMID 12750562. doi:10.4161/cbt.2.2.351.
  Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ (Mar 2003).
"MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion".
Oncogene. 22 (9): 1324–32. PMID 12618757. doi:10.1038/sj.onc.1206291.
  Li Y, Kuwahara H, Ren J, Wen G, Kufe D (Mar 2001). "The c-Src tyrosine kinase
regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta
and beta-catenin". The Journal of Biological Chemistry. 276 (9): 6061–4. PMID 11152665.
doi:10.1074/jbc.C000754200.
  Ren J, Li Y, Kufe D (May 2002). "Protein kinase C delta regulates function of the
DF3/MUC1 carcinoma antigen in beta-catenin signaling". The Journal of Biological
Chemistry. 277 (20): 17616–22. PMID 11877440. doi:10.1074/jbc.M200436200.
  Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, Carraway KL, Kufe D (Sep 2001). "The
epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma
antigen with c-Src and beta-catenin". The Journal of Biological Chemistry. 276 (38): 35239–
42. PMID 11483589. doi:10.1074/jbc.C100359200.
  Kennell JA, O'Leary EE, Gummow BM, Hammer GD, MacDougald OA (Aug 2003). "T-
cell factor 4N (TCF-4N), a novel isoform of mouse TCF-4, synergizes with beta-catenin to
coactivate C/EBPalpha and steroidogenic factor 1 transcription factors". Molecular and
Cellular Biology. 23 (15): 5366–75. PMC 165725  . PMID 12861022.
doi:10.1128/MCB.23.15.5366-5375.2003.
  Mizusaki H, Kawabe K, Mukai T, Ariyoshi E, Kasahara M, Yoshioka H, Swain A,
Morohashi K (Apr 2003). "Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia
congenita critical region on the X chromosome, gene 1) gene transcription is regulated by
wnt4 in the female developing gonad". Molecular Endocrinology. 17 (4): 507–19.
PMID 12554773. doi:10.1210/me.2002-0362.
  Ge X, Jin Q, Zhang F, Yan T, Zhai Q (Jan 2009). "PCAF acetylates {beta}-catenin and
improves its stability". Molecular Biology of the Cell. 20 (1): 419–27. PMC 2613091  .
PMID 18987336. doi:10.1091/mbc.E08-08-0792.
  Behrens J (Oct 2008). "One hit, two outcomes for VHL-mediated tumorigenesis". Nature
Cell Biology. 10 (10): 1127–8. PMID 18830218. doi:10.1038/ncb1008-1127.
  Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y (Jun 2003). "The protein tyrosine
phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates beta-
catenin". Molecular Biology of the Cell. 14 (6): 2520–9. PMC 194899  . PMID 12808048.
doi:10.1091/mbc.E02-09-0577.
  Aicher B, Lerch MM, Müller T, Schilling J, Ullrich A (Aug 1997). "Cellular
redistribution of protein tyrosine phosphatases LAR and PTPsigma by inducible proteolytic
processing". The Journal of Cell Biology. 138 (3): 681–96. PMC 2141638  . PMID 9245795.
doi:10.1083/jcb.138.3.681.
  Fuchs M, Müller T, Lerch MM, Ullrich A (Jul 1996). "Association of human protein-
tyrosine phosphatase kappa with members of the armadillo family". The Journal of
Biological Chemistry. 271 (28): 16712–9. PMID 8663237. doi:10.1074/jbc.271.28.16712.
  Besco JA, Hooft van Huijsduijnen R, Frostholm A, Rotter A (Oct 2006). "Intracellular
substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho/PTPRT)".
Brain Research. 1116 (1): 50–7. PMID 16973135. doi:10.1016/j.brainres.2006.07.122.
  Wang B, Kishihara K, Zhang D, Hara H, Nomoto K (Feb 1997). "Molecular cloning and
characterization of a novel human receptor protein tyrosine phosphatase gene, hPTP-J:
down-regulation of gene expression by PMA and calcium ionophore in Jurkat T lymphoma
cells". Biochemical and Biophysical Research Communications. 231 (1): 77–81.
PMID 9070223. doi:10.1006/bbrc.1997.6004.
  Yan HX, He YQ, Dong H, Zhang P, Zeng JZ, Cao HF, Wu MC, Wang HY (Dec 2002).
"Physical and functional interaction between receptor-like protein tyrosine phosphatase
PCP-2 and beta-catenin". Biochemistry. 41 (52): 15854–60. PMID 12501215.
doi:10.1021/bi026095u.
  He Y, Yan H, Dong H, Zhang P, Tang L, Qiu X, Wu M, Wang H (Apr 2005). "Structural
basis of interaction between protein tyrosine phosphatase PCP-2 and beta-catenin". Science
in China. Series C, Life Sciences / Chinese Academy of Sciences. 48 (2): 163–7.
PMID 15986889. doi:10.1007/bf02879669.
  Tesco G, Kim TW, Diehlmann A, Beyreuther K, Tanzi RE (Dec 1998). "Abrogation of
the presenilin 1/beta-catenin interaction and preservation of the heterodimeric presenilin 1
complex following caspase activation". The Journal of Biological Chemistry. 273 (51):
33909–14. PMID 9852041. doi:10.1074/jbc.273.51.33909.
  Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine
F, Koo EH (Jun 1999). "Presenilin 1 facilitates the constitutive turnover of beta-catenin:
differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling
pathway". The Journal of Neuroscience. 19 (11): 4229–37. PMID 10341227.
  Murayama M, Tanaka S, Palacino J, Murayama O, Honda T, Sun X, Yasutake K,
Nihonmatsu N, Wolozin B, Takashima A (Aug 1998). "Direct association of presenilin-1 with
beta-catenin". FEBS Letters. 433 (1–2): 73–7. PMID 9738936. doi:10.1016/S0014-
5793(98)00886-2.
  Puppo F, Thomé V, Lhoumeau AC, Cibois M, Gangar A, Lembo F, Belotti E, Marchetto
S, Lécine P, Prébet T, Sebbagh M, Shin WS, Lee ST, Kodjabachian L, Borg JP (Jan 2011).
"Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling".
EMBO Reports. 12 (1): 43–9. PMID 21132015. doi:10.1038/embor.2010.185.
  Bauer A, Huber O, Kemler R (Dec 1998). "Pontin52, an interaction partner of beta-
catenin, binds to the TATA box binding protein". Proceedings of the National Academy of
Sciences of the United States of America. 95 (25): 14787–92. PMC 24527  . PMID 9843967.
doi:10.1073/pnas.95.25.14787.
  Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H (Sep 2001). "The
chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene
activation". The EMBO Journal. 20 (17): 4935–43. PMC 125268  . PMID 11532957.
doi:10.1093/emboj/20.17.4935.
  Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K (Dec 1999). "The
deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin". Genes to Cells. 4
(12): 757–67. PMID 10620020. doi:10.1046/j.1365-2443.1999.00297.x.
  Lewalle JM, Bajou K, Desreux J, Mareel M, Dejana E, Noël A, Foidart JM (Dec 1997).
"Alteration of interendothelial adherens junctions following tumor cell-endothelial cell
interaction in vitro". Experimental Cell Research. 237 (2): 347–56. PMID 9434630.
doi:10.1006/excr.1997.3799.
  Shasby DM, Ries DR, Shasby SS, Winter MC (Jun 2002). "Histamine stimulates
phosphorylation of adherens junction proteins and alters their link to vimentin". American
Journal of Physiology. Lung Cellular and Molecular Physiology. 282 (6): L1330–8.
PMID 12003790. doi:10.1152/ajplung.00329.2001.

153.  Sinn HW, Balsamo J, Lilien J, Lin JJ (Sep 2002). "Localization of the novel
Xin protein to the adherens junction complex in cardiac and skeletal muscle during
development". Developmental Dynamics. 225 (1): 1–13. PMID 12203715.
doi:10.1002/dvdy.10131.
Further reading
 Kikuchi A (Feb 2000). "Regulation of beta-catenin signaling in the Wnt pathway".
Biochemical and Biophysical Research Communications. 268 (2): 243–8.
PMID 10679188. doi:10.1006/bbrc.1999.1860.
 Wilson PD (Apr 2001). "Polycystin: new aspects of structure, function, and
regulation". Journal of the American Society of Nephrology. 12 (4): 834–45.
PMID 11274246.
 Kalluri R, Neilson EG (Dec 2003). "Epithelial-mesenchymal transition and its
implications for fibrosis". The Journal of Clinical Investigation. 112 (12): 1776–84.
PMC 297008  . PMID 14679171. doi:10.1172/JCI20530.
 De Ferrari GV, Moon RT (Dec 2006). "The ups and downs of Wnt signaling in
prevalent neurological disorders". Oncogene. 25 (57): 7545–53. PMID 17143299.
doi:10.1038/sj.onc.1210064.